A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Protocol: 
AAAR4394
Phase: 
I

A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to measure the effectiveness and safety of an investigational drug called alovicidib in combination with cytarabine and daunorubicin in the treatment of AML. Investigational means that this drug has not been approved by the FDA. Cytarabine and daunorubicin are both standard of care treatments for patients with AML.

Subjects participating in this clinical trail may remain on study for 3-9 months, depending on how they respond to treatment.

Are you Eligible? (Inclusion Criteria)

1) Subject must be between 18 and 65 years of age.
2) Subjects must have a confirmed diagnosis of AML.
3) Subjects must be in good physical shape. This means that subjects must be able to walk, care for themselves, and do light physical activities such as light housework or office work.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States